Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Restructuring Costs (2020 - 2024)

Aytu Biopharma has reported Restructuring Costs over the past 3 years, most recently at $1.3 million for Q4 2024.

  • Quarterly Restructuring Costs changed N/A to $1.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Sep 2025, down 55.2% year-over-year, with the annual reading at $2.1 million for FY2025, 2.55% down from the prior year.
  • Restructuring Costs was $1.3 million for Q4 2024 at Aytu Biopharma, up from $784000.0 in the prior quarter.
  • Over five years, Restructuring Costs peaked at $2.9 million in Q1 2021 and troughed at -$3.2 million in Q2 2021.
  • The 3-year median for Restructuring Costs is $814277.0 (2020), against an average of $709262.2.
  • The largest YoY upside for Restructuring Costs was 832.23% in 2021 against a maximum downside of 494.34% in 2021.
  • A 3-year view of Restructuring Costs shows it stood at $1.3 million in 2020, then plummeted by 344.74% to -$3.2 million in 2021, then soared by 141.02% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for AYTU's Restructuring Costs are $1.3 million (Q4 2024), $784000.0 (Q3 2024), and $1.9 million (Q2 2024).